Liver Cancer
Liver cancer, also known as hepatic cancer, starts in the liver's hepatocytes, with hepatocellular carcinoma being the most common type. It can be primary, originating in the liver, or metastatic, where cancer spreads to the liver from other parts of the body, with the latter being more common and instances increasing globally.
Health Outcomes
- Accelerated Recovery in Immunocompromised Mice
- Activated p53/BAX-Mediated DNA Damage Response
- Alleviated Organ Injury
- Altered Spermidine Levels
- Delayed Tumor Onset
- Downregulated Hippo Pathway Kinase Activity
- Elevated Alkaline Phosphatase Levels
- Enhanced Alkaline Phosphatase Activity
- Enhanced Anticancer Capacity
- Enhanced Antioxidant Defense
- Enhanced Antioxidant Metabolism
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced Carcinogenic Heterocyclic Amine Transformation
- Enhanced Caspase-3 Activity
- Enhanced Cell Adhesion Capacity
- Enhanced Cell Viability
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced Glycolysis Pathway Activation
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Pro-Apoptotic MAPK Signaling
- Enhanced Tumor-Targeted Drug Delivery
- Improved Aflatoxin B1 Degradation
- Improved CST Status to CST I
- Improved Cell Viability
- Improved Child-Pugh Score
- Improved Enzyme Activity
- Improved Growth in Bile-Containing Medium
- Improved Hepatic Damage
- Improved Hepatopancreas Health
- Improved Histopathological Indicators
- Improved Histopathological Protection
- Improved Liver Antioxidant Capacity
- Improved Liver Health
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Overall Survival
- Improved Oxidative Stress Tolerance
- Improved Resistance to Sodium Selenite
- Improved Serum Biochemical HA Levels
- Improved Survival Capacity
- Improved Survival Rate
- Improved Survival Through Digestive Tract
- Improved Survival Under Gastrointestinal Conditions
- Improved Survival at 24 Months
- Improved Survival in Digestive Environment
- Improved Treatment Response Rate
- Improved Tumor Response
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Alkaline Phosphatase Activity in Skin Mucus
- Increased Alkaline Phosphatase Level
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Antiapoptotic Activity
- Increased Anticancer Activity
- Increased Binding of Carcinogenic Compounds
- Increased Catalase Levels
- Increased Cell Death
- Increased Cell Division
- Increased Cellular Adhesion
- Increased Cellular Apoptosis
- Increased Chromosomal Instability
- Increased Cure Rate after Conventional Treatment
- Increased Cytoprotection Against Tissue Damage
- Increased DNA Damage
- Increased Expression of Pro-apoptotic Proteins
- Increased Fecal Excretion of Aflatoxin B1
- Increased Glutathione Level
- Increased Glycolysis Pathway Activity
- Increased Hyaluronic Acid Production
- Increased Hydrogen Peroxide Production
- Increased Intratumoral Accumulation
- Increased KLF4 Protein Levels
- Increased Lesion Detection Rate
- Increased Parabenzoylaminobenzoic Acid Concentration
- Increased Peroxidase Activity
- Increased Polyamine Production
- Increased Pro-apoptotic Factor Levels
- Increased Reduced Glutathione Level
- Increased Sex Hormone-Binding Globulin Level
- Increased Survival in Tumor-Bearing Mice
- Increased Tissue Invasion
- Increased Viable Cell Antioxidant Activity
- Increased Vitamin B12 Level
- Increased Vitamin B12 Levels
- Increased mTORC1 Activation
- Induced Apoptosis
- Induction of Specific CD8+ T Cells
- Inhibited Activation of Apoptotic Biomarkers
- Inhibited PI3K-Akt-mTOR Signaling
- Inhibited PI3K/AKT Pathway
- Liver Protection from Aflatoxin B1 Damage
- Maintained Albumin Levels
- Maintained Natural Killer Cell Activity
- Maintained Normal ALT Levels
- Modulated Immune Marker IFN-γ
- Modulated Metabolite Profile
- Neutralized Reactive Oxygen Species
- No Significant Change in Aflatoxin Distribution or Metabolism
- Overall Treatment Success
- Reduced AFB1-Induced Liver Damage
- Reduced Acute Liver Injury
- Reduced Aminotransferase Level
- Reduced Ammonia Levels
- Reduced Apoptosis Due to Carcinogens
- Reduced Aspartate Transaminase Activity
- Reduced Butyrylcholinesterase Activity
- Reduced CEA Levels
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Specific Mortality
- Reduced Carcinogenesis
- Reduced Caspase-3 Activity
- Reduced Cell Adhesion
- Reduced Cell Apoptosis
- Reduced Clonorchiasis Severity
- Reduced Creatinine Level
- Reduced Cumulative Mortality from Vibrio vulnificus
- Reduced Cytotoxicity
- Reduced DNA Damage
- Reduced Dimethyl Sulfide Level
- Reduced Endoplasmic Reticulum Stress Markers
- Reduced Expression of Beta-Catenin
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Fas Level
- Reduced Free Radical Levels
- Reduced Fresh Frozen Plasma Transfusion
- Reduced Fumonisin B1 Levels
- Reduced GPT Level
- Reduced Genotoxicity
- Reduced Glucose Level
- Reduced Glucuronide Metabolite Level
- Reduced Glutamyl Pyruvic Transaminase Levels
- Reduced Harmful Enzyme Activity
- Reduced Hepatocellular Carcinoma Recurrence
- Reduced Histological Damage
- Reduced Histological Damage Scores
- Reduced Incidence of Abnormal Increase in Alkaline Phosphatase
- Reduced Lifespan
- Reduced Liver Function
- Reduced Liver Toxicity
- Reduced Mycotoxin Levels
- Reduced Organ Injury
- Reduced Organ Weight
- Reduced Plasma Malondialdehyde Levels
- Reduced Production of Carcinogenic Enzymes
- Reduced Pulmonary Metastasis
- Reduced Serpin Level
- Reduced Serum Alanine Aminotransferase Activity
- Reduced Serum Albumin Levels
- Reduced Serum Haptoglobin Levels
- Reduced Toxin-induced Cytotoxicity
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Reduced Urea Level
- Regenerated Hepatic Tissue
- Regulated Liver Metabolite Levels
- Safe Administration
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Stabilized Total Bilirubin Levels
- Suppressed Tumor Growth
- Targeted Tumor Reduction